



1FW

1628

ATTORNEY'S DOCKET NUMBER: 2003080-0219 (SK-943-A-US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky, *et al.* Examiner: Not Yet Assigned
Serial No.: 10/583,002 Art Unit: 1626
Filed: June 13, 2006
For: NOVEL MACROCYCLES AND USES THEREOF

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


TRANSMITTAL LETTER

Enclosed are the following documents:

1. Statement under 37 C.F.R. §§ 1.56, 1.97, and 1.98 (3 pages);
2. Form PTO-1449 (5 pages);
3. Cited Art (51 references); and
4. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,


C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

Choate, Hall & Stewart, LLP
Two International Place
Boston, MA 02110
t 617-248-5215
f 617-248-4000
chb@choate.com


Dated: August 16, 2007

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 16, 2007

Date


Signature

Vincent Montalbano

Typed or Printed Name of person signing certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: NOVEL MACROCYCLES AND USES THEREOF
Application No.: 10/583,002 Group Art No.: Not Yet Assigned
Filed: June 13, 2006 Examiner: Not Yet Assigned
For: Danishefsky, et al.
Confirmation No.: 6376
Customer Number:

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. **Preliminary Statements**

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)

The undersigned attorney certifies:

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement, and/or
- c. ☐ certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

4. ☒ Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

5. ☐ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number _____, filed on _____ of _____.

6. ☐ Concise Explanation

Documents cited above which are not in the English Language

- a. ☐ have been explained in the specification.
b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

7. ☐ Fees

☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees: If the box above is checked then please charge any fees due to Deposit Account No. 03-1721. In addition please credit any overpayment to Deposit Account No. 03-1721.



C. Hunter Baker, M.D., Ph.D.
Attorney for Applicants
Reg. No. 46,533


Choate, Hall & Stewart LLP
2 International Place
Boston, MA 02110
t 617-248-5215
f 617-248-4000
chb@choate.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet				Application Number	10/583,002
				Filing Date	June 13, 2006
				First Named Inventor	Danishefsky, et al.
				Art Unit	1626
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	2003080-0219 (SK-943-A-US)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 6,239,168	May 29, 2001	Ino et al.	
	2	US 5,977,165	November 2, 1999	Agatsuma et al.	
	3	US 5,731,343	March 24, 1998	Feng et al.	
	4	US 5,650,430	July 22, 1997	Sugimura et al.	
	5	US 5,597,846	January 28, 1997	Sugimura et al.	
	6	US 4,228,079	October 14, 1980	Calton	
	7	US 4,166,764	September 4, 1979	Calton et al.	
	8	US 4,088,658	May 9, 1978	Robertson	
	9	US 4,035,504	July 12, 1977	Hidy et al.	
	10	US 3,901,921	August 26, 1975	Urry et al.	
	11	US 3,764,614	October 9, 1973	Wehrmeister et al.	
	12	US 3,751,431	August 7, 1973	Wehrmeister et al.	
	13	US 3,621,036	February 27, 1969	Jensen et al.	
	14	US 3,373,039	March 12, 1968	Hodge et al.	
	15	US 3,373,038	March 12, 1968	Hodge et al.	
	16	US 3,239,341	March 8, 1966	Hodge et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	1	EP 0 606 044	13 July 1994			
	2	EP 0 889 042	07 January 1999			
	3	WO 98/18780	07 May 1998		X (abstract only)	
	4	WO 99/55689	04 November 1999		X (abstract only)	
	5	WO 00/61578	19 October 2000			
	6	WO 00/38674	06 July 2000			
	7	WO 01/45751	28 June 2001			
	8	WO 02/16369	28 February 2002			
	9	JP 9-202781	05 August 1997			
		Date Considered				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For

Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	1	Of	2	Application Number	10/583,002
				Filing Date	June 13, 2006
				First Named Inventor	Danishefsky, et al.
				Art Unit	1626
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	2003080-0219 (SK-943-A-US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Armstrong, et al., "Synthesis of Sulphur-Containing Heterocycles by Ring Closing Diene Metathesis", <i>Tetrahedron Letters</i> , 37 (52): 9373-9376, 1996.	
		Ayer and Lee, <i>Can. J. Microbiol.</i> , 26 : 766-773, 1980.	
		Ayer and Pena-Rodriguez, <i>Phytochem.</i> , 26 : 1353-1355, 1987.	
		Blanchette, et al., "Horner-Wadsworth-Emmons Reaction: Use of Lithium Chloride and an Amine for Base-Sensitive Compounds", <i>Tetrahedron Letters</i> , 25 (21): 2183-2186, 1984.	
		Buchner, J., "Hsp90& Co. - A Holding for Folding", <i>TIBS</i> , 136-141, 1999.	
		Chatterjee, et al., "Synthesis of Functionalized Olefins by Cross and Ring-Closing Metatheses", <i>J. Am. Chem. Soc.</i> 122 : 3783-3784, 2000.	
		Chiosis, et al., "A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells", <i>Chemistry & Biology</i> , 8 : 289-299, 2001.	
		Delmotte, et al., "A New Antifungal Substance of Fungal Origin", <i>Nature</i> , 17 : 344, 1953.	
		Fang, et al., "Regio-Diastereoselective Reactions of Dithio-Substituted Crotyllithium and Aldehydes", <i>J. Org. Chem.</i> 51 : 2828-2829, 1986.	
		Fukuyama, et al., "Total Synthesis of Gliotoxin, Dehydrogliotoxin and Hyalodendrin", <i>Tetrahedron</i> , 37 : 2045-2078, 1981.	
		Fürstner, et al., "Macrocycles by Ring-Closing-Metathesis, XI ¹ : Syntheses of (R)-(+)-Lasiiodiplodin, Zeranol and Truncated Salicylhalamides", <i>Tetrahedron</i> , 55 : 8215-8230, 1999.	
		Garbaccio, et al., "Efficient Asymmetric Synthesis of Radicol Dimethyl Ether: A Novel Application of Ring-Forming Olefin Metathesis", <i>Org. Lett.</i> 2 (20): 3127-3129, 2000.	

		Geng and Danishefsky, <i>Org. Letters</i> , 6(3): 413-6, 2004.	
		Ki, et al., <i>J. Biol. Chem.</i> , 275(50): 39231-39236, 2000.	
		Kishi, et al., "A New Method for the Synthesis of Epidithiodiketopiperazines", <i>Journal of the American Chemical Society</i> , <i>J. Am. Chem. Soc.</i> , 95(19): 6490-6492, 1973.	
		Kuduk, et al., "Synthesis and Evaluation of Geldanamycin-Estradiol Hybrids", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9: 1233-1238, 1999.	
		Kuduk, et al., "Synthesis and Evaluation of Geldanamycin-Testosterone Hybrids", <i>Bioorganic & Medicinal Chemistry Letters</i> , 10: 1303-1306, 2000.	
		Kwon, et al., "Suppression of Morphological Transformation by Radicicol is Accompanied by Enhanced Gelsolin Expression", <i>Oncogene</i> , 15: 2625-2631, 1997.	
		Kwon, et al., "Radicicol, An Agent Inducing the Reversal of Transformed Phenotypes of src-Transformed Fibroblasts", <i>Biosci. Biotech. Biochem.</i> 56(3): 538-539, 1992.	
		Lampilas, et al., "Convergent Stereospecific Total Synthesis of Monocillin I and Monorden (or Radicicol)", <i>Tetrahedron Letters</i> , 33(6): 777-780, 1992.	
		Lampilas, et al., "Convergent Stereospecific Total Synthesis of Monochiral Monocillin I Related Macrolides", <i>Tetrahedron Letters</i> , 33(6): 773-776, 1992.	
		Makara, et al., "An Improved Synthesis of 5,7-Dimethoxy-4-Methyl-Phthalide, A Key Intermediate in the Synthesis of Mycophenolic Acid", <i>Synthetic Communications</i> , 26(10): 1935-1942, 1996.	
		McCapra, et al., "The Constitution of Monorden, An Antibiotic with Tranquilising Action", <i>Tetrahedron Letters</i> , 15: 869-875, 1964.	
		Mirrington, et al., "The Constitution of Radicicol", <i>Tetrahedron Letters</i> , 7: 365-370, 1964.	
		Münster, et al., "Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells" <i>Cancer Research</i> , 61: 2945-2952, 2001.	
		Münster, et al., "Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-Induced Apoptosis in an RB-and Schedule-Dependent Manner", <i>Clinical Cancer Research</i> , 7: 2228-2236, 2001.	
		Murphy, et al., "Lithium Keten Thioacetalides. Factors Influencing α - Versus γ -Alkyl-ation", <i>J. Chem. Soc. Perkin I</i> , 2678-2682, 1980.	
		Roe, et al., "Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin", <i>J. Med. Chem.</i> 42: 260-266, 1999.	
		Sausville, Edward., "Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters" <i>Clinical Cancer Research</i> , 7: 2155-2158, 2001.	
		Schlede, et al., "Efficient Enantioselective Synthesis of a β -Hydroxyepoxide Building Block for the Construction of Macrocyclic Natural Products", <i>Tetrahedron Letters</i> , 39: 1143-1144, 1998.	
		Scholl, et al., "Synthesis and Activity of a New Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 1,3-Dimesityl-4,5-Dihydroimidazol-2-Ylidene Ligands", <i>Organic Letters</i> , 1(6): 953-956, 1999.	

		Shiotsu, et al., <i>Blood</i> , 96 (6): 2284-2291, 2000.	
		Smith, et al., "Synthesis of (-) - Bertyadionol", <i>J. Am Chem. Soc.</i> 108 : 3110-3112, 1986.	
		Solit, "394 17-(Allylamino)-17-Demethoxygeldanamycin (17-AAG) Inhibits Intra-Cellular Akt Kinase Activity in HER2 Overexpressing Breast Cancer Cell Lines and Enhances the Apoptosis Induced by Cytotoxic Agents", http://www.aacr.org/newdrugs00/394.html , 2000.	
		Uemura, et al., "Chlorination and Chloriodination of Acetylenes with Copper(II) Chloride", <i>J. Chem. Soc. Perkin I</i> , 676-680, 1977.	
		Wehrmeister and Robertson, <i>J. of Organic Chem.</i> , 33 (14): 4173-4176, 1968.	
		Yamamoto, et al., <i>Angew. Chem. Int. Ed.</i> , 42 (11): 1280-1284, 2003.	
		Yang and Danishefsky, <i>J. Am. Chem. Soc.</i> , 125 (32): 9602-3, 2003.	
		Yang, et al., <i>J. Am. Chem. Soc.</i> , 126 (25): 7881-9, 2004.	
		Zhao, et al., "Suppression of RAS and MOS Transformation by Radicicol", <i>Oncogene</i> , 11 : 161-173, 1995.	
		Zheng, et al., "Identification of a Geldanamycin Dimer that Induces the Selective Degradation of HER-Family Tyrosine Kinases", <i>Cancer Research</i> , 60 : 2090-2094, 2000.	
		International Search Report, PCT/US01/26577, Date of Mailing March 14, 2002.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.